Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma

Objectives: Our aim is to investigate the prognostic value and effect on chemotherapy toxicity of pre-treatment sarco- penia determined with positron emission tomography/computerized tomography(PET/CT) in patients with ampullary carcinoma. Methods: Characteristics of patients retrieved retrospectively. Skeletal muscle area(SMA) measurement of the muscle at L3 vertebra level was evaluated for each patient from their PET/CT scan taken at the time of diagnosis. The sex-spe- cific cut-off levels for determining sarcopenia were <38.5 cm2/m2 for females and <52.4 cm2/m2 for males. Association between oncological and radiological data was analyzed. Results: A total of 90 patients included in the study. Median age at diagnosis was 62(range: 44-77). Half of the patients were sarcopenic. Pre-treatment sarcopenia was determined as an independent variable predicting survival for both disease-free-survival(DFS) and overall survival(OS). Sarcopenic patients had statistically significant shorter OS(67.2 months for non-sarcopenic patients vs 53.2 months for sarcopenic patients, 95%CI:63.6-70.9, p<0.001), and a trend for shorter DFS(48 months for non-sarcopenic patients vs 36.8 months for sarcopenic patients, 95%CI:20.3-53.4, p=0.95) was also determined. On the other hand, chemotherapy related toxicity has also seen more in sarcopenic patients. Conclusion: Detecting the presence of pre-treatment sarcopenia may enable clinicians to predict the patient group with low survival and high probability of treatment toxicity. In order to protect this group of patients from toxicity, pre- treatment sarcopenia measurement should be applied in routine practice and should guide treatment plan.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
2. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6-to 10-year follow-up. Surgery 2006;140:764–72.
3. Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, et al. Histomolecular phenotypes and outcome in adenocarci- noma of the ampulla of vater. J Clin Oncol 2013;31:1348–56.
4. Eyigör S, Kutsal YG. Sarcopenia: again and updated. Turkish Journal of Geriatrics 2020;23:1–7.
5. Zalite IO, Zykus R, Gonzalez MF, Saygili F, Pukitis A, Gaujoux S, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pan- creatology 2015;15:19–24.
6. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Bou- dou-Rouquette P, et al. Sarcopenia and body mass index pre- dict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034–41.
7. Harimoto N, Shirabe K, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in pa- tients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013;100:1523–30.
8. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920–6.
9. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcope- nia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973–9.
10. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage 2012;44:181–91.
11. Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr 2016;35:724–30.
12. Sjøblom B, Grønberg BH, Benth JŠ, Baracos VE, Fløtten Ø, Hjermstad MJ, et al. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 2015;90:85–91.
13. Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et al. Sarcopenia is associated with toxicity in patients un- dergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol 2015;41:333–8.
14. Foster B, Boutin RD, Lenchik L, Gedeon D, Liu Y, Nittur V, et al. Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Pre- dict Health Outcomes in Patients with Sarcoma. J Nat Sci 2018;4:e502.
15. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, Mc- Cargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, indepen- dent of body mass index. J Clin Oncol 2013;31:1539–47.
16. Ritz A, Froeba-Pohl A, Kolorz J, Vigodski V, Hubertus J, Ley- Zaporozhan J, et al. Total psoas muscle area as a marker for sarcopenia is related to outcome in children with neuroblas- toma. Front Surg 2021;8:718184.
17. Goodpaster BH, Thaete FL, Kelley DE. Composition of skeletal muscle evaluated with computed tomography. Ann N Y Acad Sci 2000;904:18–24.
18. Engelke K, Museyko O, Wang L, Laredo JD. Quantitative analy- sis of skeletal muscle by computed tomography imaging- State of the art. J Orthop Translat 2018;15:91–103
19. Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with meta- static breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 2017;23:658–65.
20. Antoun S, Lanoy E, Iacovelli R, Albiges Sauvin L, Loriot Y, Merad Taoufik M, et al. Skeletal muscle density predicts prog- nosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013;119:3377–84.
21. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed to- mography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997–1006.
22. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–95.
23. Adsay NV, Basturk O, Saka B, Bagci P, Ozdemir D, Balci S, et al. Whipple made simple for surgical pathologists: orienta- tion, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol 2014;38:480–93.
24. Su H, Ruan J, Chen T, Lin E, Shi L. CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. Cancer Imaging 2019;19:82.
25. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limit- ing toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594–8.
26. Heymsfield SB, McManus CB. Tissue components of weight loss in cancer patients. A new method of study and prelimi- nary observations. Cancer 1985;55:238–49.
27. Chan MY, Chok KSH. Sarcopenia in pancreatic cancer - effects on surgical outcomes and chemotherapy. World J Gastroin- test Oncol 2019;11:527–37.
28. Kim IH, Choi MH, Lee IS, Hong TH, Lee MA. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a ret- rospective observational study. BMC Cancer 2021;21:77.
29. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531–43.
30. Mir O, Coriat R, Blanchet B, Durand J-P, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxici- ties and pharmacokinetics of sorafenib in patients with hepa- tocellular carcinoma. Plos One 2012;7:e37563.
31. Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Im- aging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 2015;6:489–97.
32. Albano D, Camoni L, Rinaldi R, Tucci A, Zilioli VR, Muzi C, et al. Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenua- tion correction CT of 18F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation. Br J Radiol 2021;94:20200672.
33. Albano D, Pasinetti N, Dondi F, Giubbini R, Tucci A, Bertagna F. Prognostic role of pre-treatment metabolic parameters and sarcopenia derived by 2-[18F]-FDG PET/CT in elderly mantle cell lymphoma. J Clin Med 2022;11:1210.
34. Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, et al. Impact of different palliative systemic treat- ments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle 2018;9:909–19.
35. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Work- ing Group for Sarcopenia. J Am Med Dir Assoc 2014;15:95– 101.
36. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sar- copenia in older people. Age Ageing 2010;39:412–23.
37. Ufuk F, Herek D. Reference skeletal muscle mass values at L3 Vertebrae level based on computed tomography in healthy Turkish adults. Int J Geront 2019;13:221–5.

APA	Basoglu tuylu T, Özgüven S, Engur C, AKAGÜNDÜZ F, Demircan N, ARIKAN R, Temiz F, ışık s, ŞENGÜN HOYUR S, Akın Telli T, çelebi a, Yasar A, Ercelep Ö, Dane F, Yumuk P (2023). Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. , 32 - 41. 10.14744/ejmi.2023.28845
Chicago	Basoglu tuylu Tugba,Özgüven Salih,Engur Ceren Ozge,AKAGÜNDÜZ FIRAT,Demircan Nazım Can,ARIKAN RUKİYE,Temiz Fatma,ışık selver,ŞENGÜN HOYUR Selma,Akın Telli Tugba,çelebi abdussamet,Yasar Alper,Ercelep Özlem,Dane Faysal,Yumuk Perran Fulden Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. (2023): 32 - 41. 10.14744/ejmi.2023.28845
MLA	Basoglu tuylu Tugba,Özgüven Salih,Engur Ceren Ozge,AKAGÜNDÜZ FIRAT,Demircan Nazım Can,ARIKAN RUKİYE,Temiz Fatma,ışık selver,ŞENGÜN HOYUR Selma,Akın Telli Tugba,çelebi abdussamet,Yasar Alper,Ercelep Özlem,Dane Faysal,Yumuk Perran Fulden Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. , 2023, ss.32 - 41. 10.14744/ejmi.2023.28845
AMA	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. . 2023; 32 - 41. 10.14744/ejmi.2023.28845
Vancouver	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. . 2023; 32 - 41. 10.14744/ejmi.2023.28845
IEEE	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P "Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma." , ss.32 - 41, 2023. 10.14744/ejmi.2023.28845
ISNAD	Basoglu tuylu, Tugba vd. "Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma". (2023), 32-41. https://doi.org/10.14744/ejmi.2023.28845

APA	Basoglu tuylu T, Özgüven S, Engur C, AKAGÜNDÜZ F, Demircan N, ARIKAN R, Temiz F, ışık s, ŞENGÜN HOYUR S, Akın Telli T, çelebi a, Yasar A, Ercelep Ö, Dane F, Yumuk P (2023). Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. Eurasian Journal of Medical Investigation, 7(1), 32 - 41. 10.14744/ejmi.2023.28845
Chicago	Basoglu tuylu Tugba,Özgüven Salih,Engur Ceren Ozge,AKAGÜNDÜZ FIRAT,Demircan Nazım Can,ARIKAN RUKİYE,Temiz Fatma,ışık selver,ŞENGÜN HOYUR Selma,Akın Telli Tugba,çelebi abdussamet,Yasar Alper,Ercelep Özlem,Dane Faysal,Yumuk Perran Fulden Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. Eurasian Journal of Medical Investigation 7, no.1 (2023): 32 - 41. 10.14744/ejmi.2023.28845
MLA	Basoglu tuylu Tugba,Özgüven Salih,Engur Ceren Ozge,AKAGÜNDÜZ FIRAT,Demircan Nazım Can,ARIKAN RUKİYE,Temiz Fatma,ışık selver,ŞENGÜN HOYUR Selma,Akın Telli Tugba,çelebi abdussamet,Yasar Alper,Ercelep Özlem,Dane Faysal,Yumuk Perran Fulden Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. Eurasian Journal of Medical Investigation, vol.7, no.1, 2023, ss.32 - 41. 10.14744/ejmi.2023.28845
AMA	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. Eurasian Journal of Medical Investigation. 2023; 7(1): 32 - 41. 10.14744/ejmi.2023.28845
Vancouver	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. Eurasian Journal of Medical Investigation. 2023; 7(1): 32 - 41. 10.14744/ejmi.2023.28845
IEEE	Basoglu tuylu T,Özgüven S,Engur C,AKAGÜNDÜZ F,Demircan N,ARIKAN R,Temiz F,ışık s,ŞENGÜN HOYUR S,Akın Telli T,çelebi a,Yasar A,Ercelep Ö,Dane F,Yumuk P "Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma." Eurasian Journal of Medical Investigation, 7, ss.32 - 41, 2023. 10.14744/ejmi.2023.28845
ISNAD	Basoglu tuylu, Tugba vd. "Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma". Eurasian Journal of Medical Investigation 7/1 (2023), 32-41. https://doi.org/10.14744/ejmi.2023.28845